Mr. Ibrahem/Patiromer
Clinical data
Trade namesVeltassa
Other namesRLY5016
AHFS/Drugs.comMonograph
MedlinePlusa616012
License data
Pregnancy
category
  • AU: B1
Routes of
administration
By mouth (suspension)
Drug classPotassium binder[1]
Legal status
Legal status
Pharmacokinetic data
BioavailabilityNot absorbed
MetabolismNone
Onset of action7 hrs; 1-2 wks for max effect[1]
Duration of action24 hrs
ExcretionFeces
Chemical and physical data
Formula[(C3H3FO2)182·(C10H10)8·(C8H14)10]n
[Ca91(C3H2FO2)182·(C10H10)8·(C8H14)10]n (calcium salt)

Patiromer, sold under the brand name Veltassa, is a medication used to treat high blood potassium.[1] It is taken by mouth.[1] Its onset of action begins in about 7 hours, with maximum efforts taking a week or two.[1]

Common side effects include constipation, low blood magnesium, nausea, and abdominal pain.[1] Other side effects may include high calcium and intestinal perforation.[4] It works by binding potassium in the gut, increasing its loss in the stool.[2]

Patiromer was approved for medical use in the United States in 2015 and Europe in 2017.[1][3] In the United Kingdom it costs the NHS about £170 per month as of 2021.[4] This amount in the United States costs about 1,000 USD.[5]

References edit

  1. ^ a b c d e f g h i "Patiromer Sorbitex Calcium Monograph for Professionals". Drugs.com. February 2017. Archived from the original on 13 November 2019. Retrieved 13 November 2019.
  2. ^ a b c "Veltassa- patiromer powder, for suspension". DailyMed. 23 October 2019. Archived from the original on 20 October 2020. Retrieved 18 October 2020.
  3. ^ a b "Veltassa". Archived from the original on 21 October 2020. Retrieved 26 October 2021.
  4. ^ a b BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1105. ISBN 978-0857114105.
  5. ^ "Veltassa Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 24 August 2019. Retrieved 26 October 2021.